COVID-19

COVID-19

LSTM plays a unique role in the response to COVID-19. It partners with multiple institutions and organisations aimed to have immediate benefits for public health in the UK and overseas.

Within LSTM a lot of research is conducted via the Centre for Drugs and Diagnostics (CDD). This centre comprises an experienced multi-disciplinary group of experts working together researching, developing and validating drugs and diagnostics in response to the COVID-19 pandemic. It uses state-of-the art laboratories and equipment and works closely with industry, NHS and academia. 

Research into vaccines is the only way to find out which vaccines will work. LSTM plays a key role in the various COVID-19 vaccine research programmes that are ongoing.

LSTM also partners with multiple other institutions and organisations to provide evidence based advisory services to government departments and other interested parties.

In addition, LSTM, the University of Liverpool (UoL) and the NHS, represented by Liverpool Health Partners (LHP), have united to redirect the majority of Liverpool's research efforts to COVID-19. The research programmes are designed to have immediate benefits for public health and are underpinned by equipment and laboratory space across the Liverpool City Region. 

Other key partners are Liverpool City Council (LCC) and Malawi-Liverpool Wellcome Trust Clinical Research Programme (MLW).

COVID-19 Latest news